Prime Minister Boris Johnson, who opened a conference hosted by the Coalition for Epidemic Preparedness Innovations (CEPI) in London via video, hailed a new partnership between CEPI and DIOSynVax, a biotech spinout of the University of Cambridge. The team at DIOSynVax is working on a vaccine technique to tackle known Covid variants and future ones, together with viruses that cause illnesses such as Sars and Mers.
Mr Johnson said: "The UK is proud to have committed to a quarter of a billion pounds to support CEPI at the start of the pandemic, because it was precisely the partnership between CEPI, government, industry and academia which helped our vaccines to triumph over the virus.
"And now, we must come together to support CEPI's global plan for the next generation of vaccine technologies, such as the new variant-proof vaccine being developed at Cambridge University to help protect us against the next Covid variant, or indeed, against the next pandemic."
